Older people, those with multimorbidity, and those with specific underlying health
conditions remain at increased risk of COVID-19 hospitalisation and death after the
initial vaccine booster and should, therefore, be prioritised for additional boosters,
including novel optimised versions, and the increasing array of COVID-19 therapeutics.